- CCR9 inhibition does not interfere with the development of immune tolerance to oral antigensMatthew J Walters
ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States
Immunol Lett 151:44-7. 2013..These results highlight the inadequacy of genetic deletion of CCR9 when predicting the effects of pharmacological CCR9 inhibition on intestinal biology...
- Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel diseaseMatthew J Walters
ChemoCentryx, Inc, Mountain View, CA 94043, USA
J Pharmacol Exp Ther 335:61-9. 2010..Analysis of the plasma level of drug associated with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation...